# FDA Approves First-in-Class NDSRI for ADHD in Adults and Children
The FDA has approved a new medication class for attention deficit hyperactivity disorder. This first-in-class norepinephrine-dopamine reuptake inhibitor, known as an NDSRI, expands treatment options for both adults and children with ADHD.
The approval marks a significant advancement in pharmacological treatment for the disorder. NDSRIs work by increasing levels of two key neurotransmitters in the brain: norepinephrine and dopamine. These chemicals regulate attention, impulse control, and executive function. By preventing the brain from reabsorbing these neurotransmitters, NDSRIs help maintain higher concentrations in neural pathways involved in focus and behavioral regulation.
Until now, ADHD treatment relied primarily on stimulant medications like methylphenidate and amphetamine-based drugs, or older non-stimulant options such as atomoxetine and guanfacine. This new class offers a different mechanism, potentially benefiting patients who don't respond adequately to existing therapies or experience unacceptable side effects from current options.
The FDA based its approval on clinical trial data demonstrating the medication's effectiveness and safety profile in both pediatric and adult populations. Researchers documented improvements in attention, impulse control, and overall ADHD symptom severity. The trials also tracked adverse effects, establishing a side effect profile physicians can reference when considering treatment.
ADHD affects approximately 6.1 million children and 10.2 million adults in the United States. Many patients cycle through multiple medications before finding an effective match, creating a substantial need for novel treatment approaches. This approval gives prescribers another evidence-based tool when first-line medications fail.
Patients considering this medication should discuss its benefits and risks